Key stats
About Virtus LifeSci Biotech Clinical Trials ETF
Home page
Inception date
Dec 16, 2014
Structure
Open-Ended Fund
Distributes
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Tax on distributions
Qualified dividends
Primary advisor
Virtus ETF Advisers LLC
Distributor
VP Distributors LLC
BBC focuses on biotech companies with lead drugs that are still in various phases of clinical trials and not yet approved marketing. Given the low historical success rates in clinical trials, the fund is a high-risk and high-reward bet on a small subset of biotech companies. It excludes companies with a lead drug candidate thats still in preclinical testing or research stage, prior to entering into human clinical trials. Also excluded are the following 12 distinct sub-industries: Animal Health, Diversified Healthcare, Investment Management, Healthcare Services, Non-Healthcare, Large Pharmaceuticals, Specialty Pharmaceuticals, Medical Devices, Vaccines, Nutraceuticals, OTC Healthcare, or Tools. As such, investors looking for broad biotech exposure, won't find it in BBC. The Index Committee utilizes various public data sources to select portfolio holdings, including, SEC filings, public documents from the U.S. FDA, company press releases and official corporate websites.
Classification
What's in the fund
Exposure type
Health Technology
Stock breakdown by region
Displays a symbol's price movements over previous years to identify recurring trends.